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Background. Calreticulin controls the C/EBPαp42/p30 at the translational level trough a cis-regulatory CNG rich loop in the
CEBPA mRNA. We determined the eﬀects of steroids and long-acting beta-agonists on the p42/p30 ratio and on calreticulin
expression in primary human bronchial smooth muscle (BSM) cells. Methods. The eﬀects of budesonide (10−8 M) and formoterol
(10−8 M) were studied in BSM cells pre-treated with siRNA targeting calreticulin. The expression of C/EBPα and calreticulin was
determinedbyimmuno-blotting.Automatedcellcountswereperformedtomeasureproliferation.Results.AlltestedBSMcelllines
(n = 5) expressed C/EBPα and calreticulin. In the presence of 5% FBS, the p42/p30 ratio signiﬁcantly decreased (n = 3, P<0.05)
and coincided with BSM cell proliferation. High levels of calreticulin were associated with a decreased p42/p30 isoform ratio. FBS
induced the expression of calreticulin (n = 3, P<0.05), which was further increased by formoterol. siRNA targeting calreticulin
increased the p42/p30 ratio in non-stimulated BSM cells and signiﬁcantly inhibited the proliferation of PDGF-BB-stimulated
BSM cells (n = 5, P<0.05). Neither budesonide nor formoterol restored the p42 isoform expression. Conclusions. Our data show
calreticulinisanegativeregulatorofC/EBPαproteinexpressioninBSMcells.Modulationofcalreticulinlevelsmayprovideanovel
target to reduce BSM remodeling.
1.Introduction
An important feature of asthma pathology is airway wall
remodeling, characterized by a thickened basement mem-
brane and an increase with respect to the bulk of the bron-
chial smooth muscle (BSM) cells [1–3]. Earlier we showed
that the increased proliferation rate of asthmatic BSM cells
was normalized after the introduction of an expression vec-
tor for full length C/EBPα mRNA [4]. We have further pro-
vided data showing a disease speciﬁc expression of C/EBP-
isoforms in asthma and COPD [5].
C/EBPα can be expressed as full length and truncated
protein isoforms, commonly referred to as p42 and p30. The
full length C/EBPα (p42) functions as a proliferation inhi-
bitor,whereasthetruncatedC/EBPα(p30)doesnothavethis
eﬀect [6, 7]. A decreased p42/p30 ratio may therefore render
BSM cells a growth advantage and result in thicker layers
of muscles around the airways as observed in the lungs of
asthma patients.
The standard therapy for asthma consists of drugs that
reduce airway inﬂammation (predominantly glucocorti-
coids) and induce relaxation of the smooth muscles (pre-
dominantly β2-agonists). We have earlier shown the molecu-
lar biological basis of the interaction of both classes of drugs,
which involved the formation of a complex consisting of the
glucocorticoid receptor and C/EBPα [8–11]. This complex is
abletoactivatethecellcycleinhibitorp21cip1/waf1 [9,10],thus
demonstratinganinteractivenegativeregulatorynetworkfor
cell proliferation. The observed diminished expression of
C/EBPα in BSM cells of asthma patients is mainly due to
posttranscriptional regulation aﬀecting the translation of the
CEBPA mRNA [12, 13].
In general, two mechanisms can be involved in trans-
lation control: “global” and “selective”. Global control acts
on all mRNAs in a nonspeciﬁc manner, whereas selective
translation regulation targets a speciﬁc subset of mRNAs.
These speciﬁc mRNAs often have cis-regulatory sequences
that sense subtle changes in the activity of the translation2 Journal of Allergy
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Figure 1: (a) Simpliﬁed scheme of the CEBPA mRNA. Due to alternative translation start sites (A, B, and C), full length (p42) and truncated
(p30) C/EBPα proteins with distinct functions can be formed. Start site B is out of frame and determines whether A or B is accessible for
translation, hence producing either p42 or p30 C/EBPα proteins. (b) Schematic representation showing three important signaling pathways
for the translation control of CEBPA messenger RNA: (1) the pathway leading to activation of the eukaryotic initiation factors eIF2 and
eIF2B, which is counteracted by hnRNPE2, (2) the pathway of mTOR and eukaryotic initiation factor 4E (eIF4E), which is inhibited by
4E-BP1, and (3) the pathway leading to calreticulin (CRT) expression, a protein that binds to a double-stranded RNA loop and prevents the
translation of full length C/EBPα proteins. Abbreviations: 5  TOP: 5  tract of pyrimidine; mTOR: mammalian target of rapamycin.
machinery or form loops that aﬀect the accessibility of the
appropriate translation start sites. It is now well documented
that the CEBPA mRNA can be expressed as a full length pro-
tein (p42) or a truncated form (p30) [6, 7, 14–18]. The
p42/p30 ratio is predominantly controlled at the transla-
tional level [15–18]. Full lengths (p42) and truncated (p30)
C/EBPα proteins are generated from one single 5  tract of
pyrimidine(5  TOP)CEBPAmRNA(Figure 1(a)).Threeim-
portantsignalingpathwaysregulatethetranslationof5  TOP
messengers (Figure 1(b)). The ﬁrst is the ubiquitous eukary-
otic initiation factor 2 (eIF2). The second is leading to acti-
vation of mammalian target of rapamycin (mTOR) and sub-
sequent activation of eukaryotic initiation factor 4E (eIF4E).
These pathways are stringently controlled by speciﬁc in-
hibitory proteins, including hnRNPE2, which interferes with
translation initiation, and 4E-BP1, a protein that prevents
ribosomal scanning [19]. The third level of control of
CEBPA mRNA translation is found in a cis-regulatory dou-
ble-stranded RNA loop, which provides a docking site for
calreticulin. When calreticulin is bound to this sequence,
translation of the full length C/EBPα (p42) is reduced [20].
Here, we isolated and maintained primary human BSM
cells and studied the involvement of calreticulin in the regu-
lation of CEBPA mRNA translation and whether budesonide
and formoterol are able to modulate the p42/p30 ratio.
2.MaterialandMethods
2.1. Tissue Specimens and Cell Cultures. Lung tissue speci-
mens were obtained from the Department of Internal Med-
icine, Pneumology, and the Department of Thorax Surgery,
University Hospital Basel, Switzerland, with the approval
of the local Ethical Committee and written consent of all
patients. BSM cells were established as previously describedJournal of Allergy 3
[10] and grown in RPMI 1640 (Lonza, Basel, Switzerland)
supplemented with 5% fetal bovine serum (FBS), 8mM
L-glutamine, 20mM HEPES, and 1% MEM vitamin mix
(Gibco, Paisley, UK). Neither antibiotics nor antimycotics
were added at any time.
2.2. Cell Treatment and Drugs. Conﬂuent BSM cells were
cultured for 24 hours in the presence or absence of 5% FBS
andgrowninthepresenceofanoptimalconcentration[4,8–
10]o fb u d e s o n i d e( 1 0 −8M), formoterol (10−8M), or a com-
bination of both drugs for 24 and 96 hours.
2.3. Small Inhibitory RNA (siRNA) Treatment. Transfection
with siRNA for calreticulin or negative control (Ambion,
Austin, USA) was performed according manufacturer pro-
tocol. Cells (70% conﬂuence) were plated into 6 well plates
and transiently transfected with siRNA (50nM) for 6 hours.
Thereafter, fresh RPMI was added for 24 hours. Then, cells
were cultured in presence or absence of budesonide (10−8M)
or formoterol (10−8M). Cell lysates were collected after 24
hours and prepared for immuneblot analysis.
2.4. Protein Isolation and Analysis by Immunoblot. Cellular
proteins were isolated from conﬂuent cells by dissociation
in lysis buﬀer (62,5mM Tris-HCl (pH 6.8), 2% SDS, 2% β-
mercaptoethanol, 10% glycerol) and denaturation in sample
buﬀer (3x Laemmli buﬀer with β-mercapto-ethanol) and
boiling for 5min. Equal protein amounts were loaded onto
a 4–12% PAGE-gel (Pierce Biotech, Thermo Fisher Scientif-
ic, Rockford, IL, USA) and were size fractionated by elec-
trophoresis (1hr, 100V, open A). The gel was sandwiched
between two nitrocellulose membranes (Biorad, Reinach,
Switzerland), and proteins were transferred (transfer buﬀer:
0.05M NaCl, 2mM Na-EDTA, 0.1mM DTT, 10mM, Tris
HCl (pH 7.5)) overnight (50◦C). Protein transfer and equal
loading were conﬁrmed by Ponceau’s staining. The mem-
branes were blocked (10min) in 3% bovine serum albumin
(Roche, Rotkreuz, Switzerland) in 1x phosphate buﬀered
saline with 0.05% Tween-20 (PBST). The membranes were
incubated(1hour)atroomtemperature(RT)withoneofthe
antibodiestoC/EBPα(SantaCruzBiotech,SantaCruz,USA)
and calreticulin (Santa Cruz Biotech). Membranes were then
washed (3 × 5min) and incubated (1 hour, RT) with horse-
radish labeled species-speciﬁc antibodies (Santa Cruz Bio-
tech). The membranes were washed (3 × 5min) with and
incubated (5min) with ECL-substrate (Pierce), and protein
bands were visualized on X-ray ﬁlms (Fuji Film, Medical X-
rayﬁlm,Luzern,Switzerland).Proteinbandsweresemiquan-
tiﬁed by an image analysis system (ImageJ). Protein expres-
sion was normalized to α-tubulin as internal control. The
presented p42/p30 ratios were calculated from normalized
densitometry data.
2.5. Proliferation. BSM cells were plated in a 24 wells plate at
ad e n s i tyo f1 0 4 cells/well. Next cells were grown for 24 hours
in the presence of FBS (5%), before being serum starved for
24 hours. Then, cells were incubated in absence or presence
of FBS (5%) for 96 hours. After trypsinization cells, were
counted manually and/or by using an automated particle
counter (Coulter).
2.6. Statistics. Cytokine and proliferation data are presented
as mean ± SEM, immunoblot analysis is shown as mean ±
SEM after densitometric image analysis (ImageJ software,
National Institute of Mental Health, Bethesda, MD, USA)
ofindependentexperiments.Paired/unpairedStudent’st-test
was performed, and P values <0.05 were considered signi-
ﬁcant.
3. Results
3.1. Eﬀects of FBS, Budesonide, and Formoterol on p42/30 Ra-
tios. To determine the eﬀect of FBS, budesonide, and for-
moterol on p42/p30, BSM cells (n = 3) were cultured for 0,
24, and 96 hours in growth medium (5% FBS) supple-
mented with either budesonide (10−8M) or formoterol
(10−8M). FBS (5%) signiﬁcantly reduced p42 C/EBPα levels
(n = 3; P<0.05), both after 24 and 96 hours (Figure
2(a)). Concomitantly, p30 C/EBPα levels were signiﬁcantly
increased (n = 3; P<0.05) at both time points, resulting in
reduced p42/p30 ratios which are presented in Figure 2(b).
The addition of formoterol to FBS stimulated BSM cells
further reduced the p42/p30 ratio below 0.01, whereas
budesonide did not modify the eﬀect of FBS (Figure 2(b)).
As shown in Figure 3(c), a reduced p42/p30 ratio coincided
with a signiﬁcantly increased proliferation rate of 5% FBS-
stimulated BSM cells relative to nonstimulated cells (n = 4;
P<0.05).
3.2. Calreticulin Levels Coincide with C/EBP p42/p30 Ratios.
BSM cells were incubated with FBS (5%) supplemented with
budesonide (10−8M) or formoterol (10−8M). As demon-
strated in Figure 3(a), resting BSM cells expressed low levels
of calreticulin, which were signiﬁcantly upregulated after 24
an 96 hours in the presence of 5% FBS, only. After 96 hours,
budesonide (10−8M) slightly restored the expression of the
p42 isoform, but the p42/p30 ratio was unaﬀected. The ex-
pression of calreticulin protein coincided with low levels of
C/EBPα ( p 4 2 )a n dh i g hl e v e l so fC / E B P α (p30): the p42/p30
ratio signiﬁcantly decreased (n = 3; P<0.05). As shown
in Figure 3(b), calreticulin-speciﬁc siRNA signiﬁcantly de-
creased the expression of calreticulin protein (n = 3, P<
0.05). The knockdown of calreticulin only increased the ex-
pression of C/EBPα (p42) in untreated BSM cells. Finally,
BSM cells were transfected with increasing concentrations of
calreticulin-speciﬁc siRNA and incubated in presence and
absenceofPDGF-BBfor96hours.AsdemonstratedinFigure
3(c), siRNA for calreticulin dose-dependently inhibited the
proliferation of PDGF-BB-stimulated BSM cells (n = 5; P<
0.05 for calreticulin-siRNA ranging from 0.1 to 5.0ng/mL),
whereas the control siRNA did not have an eﬀect on PDGF-
BB-induced proliferation (n = 5; P = 0.59).
4. Discussion
An increased capacity to proliferate is a key feature of BSM
cells obtained from asthma patients and may provide an4 Journal of Allergy
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Figure 2: (a) Representative immunoblot analysis demonstrating the modulatory eﬀect of asthma drugs on the C/EBPα (p42) and C/EBPα
(p30) expression pattern in human BSM cells. BSM cells were untreated (control) or incubated with 5% FBS alone, and in the presence
of budesonide (10−8M) or formoterol (10−8M) for 24 and 96 hours. Similar data were obtained in two additional cell lines. (b) C/EBPα
p42/p30 ratios (mean ± SEM; n = 3) in BSM cells cultured for 0, 24, and 96 hours with 5% FBS (solid line), budesonide (dotted line),
or formoterol (dashed line). (c) C/EBPα (p42 and p30) expression patterns projected in the proliferation curve of BSM cells. Cells were
incubated for 0, 24, and 96 hours in absence (dashed line) or presence of 5% FBS (solid line). Data are expressed as a percentage of the cell
number at t = 0 (control). ∗Signiﬁcant diﬀerence between untreated and FBS-stimulated cells (P<0.05; n = 4). Photo insets show the
corresponding ratio of C/EBPα p42 and p30 expression of one representative experiment at t = 0h (control), t = 24h, and t = 96h.
explanation for the observed increase of BSM bundles sur-
rounding the bronchi of asthma patients [21]. We have
extensively explored the role of the CEBP transcription fac-
tor-family in BSM cell proliferation and concluded that the
expressionandregulationofC/EBPαisoformsmaybecrucial
to understand the proliferation control of BSM cells [4, 5, 12,
13]. In our present study, we demonstrated that normal BSM
cells express C/EBPα (p42) and C/EBPα (p30) isoforms, as
well as their speciﬁc translation regulator calreticulin. More-
over, we observed a speciﬁc relation between these proteins,
that is, when calreticulin levels are high, the p42/p30 ratio
is small. Furthermore, we showed that in the presence of
serum, the p42/p30 ratio signiﬁcantly decreased. Addition
of budesonide, but not formoterol, slightly restored the p42
levels. Restoring p42 levels would theoretically restore the
responsiveness of BSM cells to budesonide and/or for-
moterol, since only full length C/EBPα proteins formed a
complex with the glucocorticoid receptor to induce the cell
cycle inhibitor p21cip1/waf1[9, 11]. Both budesonide and for-
moterol were unable to signiﬁcantly increase the p42/p30
ratio, however. The incapability of budesonide and for-
moterol to induce the expression of C/EBPα (p42) may ex-
plainwhytheairwayremodelingobservedinasthmapatients
is resistant to therapy involving steroids and/or β-mimetics
[22].
We have earlier reported that an impaired translation-
initiation of the CEBPA mRNA in BSM cells of asthma pa-
tients was associated with the decreased expression of the
translation regulator eIF4E [12]. We were unable to detect
signiﬁcant diﬀerences with respect to eIF4E levels betweenJournal of Allergy 5
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Figure 3: (a) Immunoanalyses demonstrating the eﬀect of asthma drugs on the C/EBPα (p42), C/EBPα (p30), and calreticulin expression
pattern. BSM cells were untreated or incubated with 5% FBS alone, and in the presence of budesonide (10−8M) or formoterol (10−8M) for
24 and 96 hours. (b) Immunoanalyses demonstrating C/EBPα (p42), C/EBPα (p30), and calreticulin expression patterns in BSM cells after
transientknockoutofthecalreticulinbysiRNA.BSMcellswereuntreatedorincubatedwith5%FBSalone,andinthepresenceofformoterol
(10−8M) for 24 hours. (c) BSM cell proliferation (presented as relative cell counts) in response to PDGF-BB (5ng/mL) and the eﬀect of
increasing concentrations calreticulin-speciﬁc siRNA relative to control siRNA (as indicated). ∗Signiﬁcant inhibition relative to PDGF-BB-
stimulated cells (P<0.05; n = 5).6 Journal of Allergy
house-dust-mite-challenged BSM cells isolated from asth-
matic and nonasthmatic subjects, however [13]. Therefore,
we proposed that calreticulin, a protein initially identiﬁed as
an endoplasmic reticulum luminal chaperone that controls
the regulation of intracellular Ca2+ homeostasis [23], could
be pivotal in the downregulation of C/EBPα translation and
may be one of the key regulators to explain low levels of
C/EBPα proteins in BSM cells of asthma patients. Binding of
calreticulin has been shown to inhibit the translation of the
CEBPA mRNA, as a result of a direct interaction of calreti-
culin and the CEBPA transcript. As depicted in Figure 1(b),
calreticulin binds to a stem loop within the CEBPA mRNA,
which is formed by internal base-pairing of the GCN repeat
motif [24]. When calreticulin is bound to this loop, transla-
tion of the full length C/EBPα (p42) can no longer be gen-
erated and p21cip1/waf1 cannot be formed. An inverse rela-
tionship of C/EBPα and calreticulin had been demonstrated
in adipocytes, where calreticulin inhibited adipogenesis by
suppressing the expression of C/EBPα [25]; an observation
that was also reported in acute myeloid leukemia [26]. Here,
we demonstrated that the same mechanism operates in nor-
malBSMcells,becauseatransientsuppressionofcalreticulin
by siRNA increased C/EBPα (p42) levels in resting BSM
cells. It should be noted, however, that in proliferating cells
additional mechanisms operate to control C/EBPα isoforms
[4, 12, 13]. Therefore, the decrease of the C/EBPα protein
level in BSM cells of asthma patients may only partially be
related to increased calreticulin.
Our current data show that in the presence of 5% FBS
BSM cells rapidly decreased the p42/p30 ratio. Formoterol
was able to even further reduce the p42/p30 values. Here, the
p42/p30 value went below 0.01, demonstrating an additive
eﬀect relative to FBS alone (Figure 2(b)). This additive eﬀect
was not observed with budesonide and indicates that formo-
terol also activates additional pathways not induced by bud-
esonide and independent of C/EBPα (p42). It should be em-
phasized that both C/EBPα (p42) and C/EBPα (p30) can
bind to the same DNA motifs but that p30 cannot exert the
antiproliferative eﬀects of p42. The p42, however, is a direct
inhibitor of cell cycle progression.
Finally, we found that the siRNA targeting calreticulin
dose-dependently inhibited BSM cells proliferation and re-
stored C/EBPα (p42) in nonstimulated BSM cells only. This
shows that, although FBS was able to induce calreticulin, it
does not exert its eﬀects through an increased expression of
calreticulin. Rather, FBS and PDGF may aﬀect the transcrip-
tionofthegenedirectlyorredirectthetranslationmachinery
to alternative start codons present in the CEBPA mRNA as
describedpreviously[14–16].Calreticulinlevelswereslightly
increased after 96 hours of treatment with formoterol. The
signiﬁcance of this observation is currently unclear, but may
indicate an additional inhibitory eﬀect on proproliferative
members of the CEBP gene family [24].
Taken together, our current data demonstrate that the
translation-controlled C/EBPα (p42) and its counterpart
(p30) are present in BSM cells. Calreticulin functions as an
important control protein for BSM cell proliferation, but
largely independent of the transactivating C/EBPα protein
isoform. However, modulation of calreticulin levels—either
(epi) geneticallyorbyadministration of speciﬁcdrugs—may
be a novel tool to target remodeling parameters involving
BSM cells, both in vitro and in vivo.
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